Investigation Launched by Pomerantz Law Firm on Neogen Corporation Investors' Claims
On October 8, 2026, Pomerantz LLP announced their investigation into claims connected to Neogen Corporation, which trades on NASDAQ under the symbol NEOG. This move follows concerning news regarding the company's veterinary product, Neogen Vet HYCOAT, which is now under scrutiny after the U.S. Food and Drug Administration (FDA) issued a warning letter. The letter referenced serious health risks, linking the product to multiple fatal infections. Specifically, it was reported that at least 20 horses tragically died, reportedly due to the contamination of the product that was initially labeled as sterile. This incident marks one of the most significant product recalls related to veterinary medical products regulated by the FDA in history.
Investigations have indicated that the FDA's warning stemmed from findings that raised alarm over the quality standards maintained by Neogen. The FDA stated that the contamination problem could lead to dire consequences, noting that these were the most equine fatalities linked to a quality defect in any FDA-regulated veterinary product to date. In January 2026, Neogen undertook a voluntary recall of HYCOAT, but the damage had already begun—on the announcement date of the FDA warning, Neogen's share price plummeted by $0.99, closing at $12.73, which translates into a significant loss of 7.22% for investors.
Pomerantz LLP, a prominent law firm with a rich legacy of fighting for shareholder rights, has long been at the forefront of addressing corporate misdeeds in cases like this. Established by Abraham L. Pomerantz, the firm has specialized in securities class actions for more than 85 years, recovering millions of dollars for affected investors across various sectors. Their proactive approach aims to uncover whether Neogen's leadership may have engaged in activities that constituted securities fraud or other illicit practices affecting investors' financial interests.
For any investors feeling concerned about their potential losses tied to Neogen Corporation, Pomerantz LLP advises reaching out to them for further information and assessments. They aim to build a case that might reflect the ongoing issues with the company's practices and the ensuing impact on public shareholders.
If you would like to join this burgeoning class action, you can contact Danielle Peyton at Pomerantz LLP either through email at [email protected] or by calling 646-581-9980, ext. 7980.
This situation highlights the critical need for transparency within corporations, particularly those like Neogen that are significantly involved in public health and safety. As the investigation continues, it is crucial for all stakeholders to remain informed about their rights and the steps they can take to seek justice against potential corporate misconduct.
Investigations have indicated that the FDA's warning stemmed from findings that raised alarm over the quality standards maintained by Neogen. The FDA stated that the contamination problem could lead to dire consequences, noting that these were the most equine fatalities linked to a quality defect in any FDA-regulated veterinary product to date. In January 2026, Neogen undertook a voluntary recall of HYCOAT, but the damage had already begun—on the announcement date of the FDA warning, Neogen's share price plummeted by $0.99, closing at $12.73, which translates into a significant loss of 7.22% for investors.
Pomerantz LLP, a prominent law firm with a rich legacy of fighting for shareholder rights, has long been at the forefront of addressing corporate misdeeds in cases like this. Established by Abraham L. Pomerantz, the firm has specialized in securities class actions for more than 85 years, recovering millions of dollars for affected investors across various sectors. Their proactive approach aims to uncover whether Neogen's leadership may have engaged in activities that constituted securities fraud or other illicit practices affecting investors' financial interests.
For any investors feeling concerned about their potential losses tied to Neogen Corporation, Pomerantz LLP advises reaching out to them for further information and assessments. They aim to build a case that might reflect the ongoing issues with the company's practices and the ensuing impact on public shareholders.
If you would like to join this burgeoning class action, you can contact Danielle Peyton at Pomerantz LLP either through email at [email protected] or by calling 646-581-9980, ext. 7980.
This situation highlights the critical need for transparency within corporations, particularly those like Neogen that are significantly involved in public health and safety. As the investigation continues, it is crucial for all stakeholders to remain informed about their rights and the steps they can take to seek justice against potential corporate misconduct.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.